Nutritional cofactor treatment in mitochondrial disorders

被引:74
作者
Marriage, B
Clandinin, MT
Glerum, DM
机构
[1] Ross Prod Div, Columbus, OH 43215 USA
[2] Univ Alberta, Dept Med Genet, Edmonton, AB, Canada
[3] Univ Alberta, Dept Med, Edmonton, AB, Canada
[4] Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB, Canada
关键词
D O I
10.1016/S0002-8223(03)00476-0
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Mitochondrial disorders are degenerative diseases characterized by a decrease in the ability of mitochondria to supply cellular energy requirements. Substantial progress has been made in defining the specific biochemical defects and underlying molecular mechanisms, but limited information is available about the development and evaluation of effective treatment approaches. The goal of nutritional cofactor therapy is to increase mitochondrial adenosine 5'-triphosphate production and slow or arrest the progression of clinical symptoms. Accumulation of toxic metabolites and reduction of electron transfer activity have prompted the use of antioxidants, electron transfer mediators (which bypass the defective site), and enzyme cofactors. Metabolic therapies that have been reported to produce a positive effect include Coenzyme Q(10) (ubiquinone); other antioxidants such as ascorbic acid, vitamin E, and lipoic acid; riboflavin; thiamin; niacin; vitamin K (phylloquinone and menadione); creatine; and carnitine. A literature review of the use of these supplements in mito- chondrial disorders is presented.
引用
收藏
页码:1029 / 1038
页数:10
相关论文
共 82 条
[1]   Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): Evaluation by noninvasive tissue oximetry [J].
Abe, K ;
Matsuo, Y ;
Kadekawa, J ;
Inoue, S ;
Yanagihara, T .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 162 (01) :65-68
[2]   MARKED REDUCTION IN CSF LACTATE AND PYRUVATE LEVELS AFTER COQ THERAPY IN A PATIENT WITH MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC-ACIDOSIS AND STROKE-LIKE EPISODES (MELAS) [J].
ABE, K ;
FUJIMURA, H ;
NISHIKAWA, Y ;
YORIFUJI, S ;
MEZAKI, T ;
HIRONO, N ;
NISHITANI, N ;
KAMEYAMA, M .
ACTA NEUROLOGICA SCANDINAVICA, 1991, 83 (06) :356-359
[3]   BIOGENESIS OF FLAVOPROTEIN AND CYTOCHROME COMPONENTS IN HEPATIC MITOCHONDRIA FROM RIBOFLAVIN-DEFICIENT RATS [J].
ADDISON, R ;
MCCORMICK, DB .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1978, 81 (01) :133-138
[4]  
Andersen CB, 1997, MOL ASPECTS MED, V18, pS307
[5]  
Androne L, 2000, IN VIVO, V14, P327
[6]   CLINICAL AND BIOCHEMICAL ASPECTS OF CARNITINE DEFICIENCY AND INSUFFICIENCY - TRANSPORT DEFECTS AND INBORN-ERRORS OF BETA-OXIDATION [J].
ANGELINI, C ;
VERGANI, L ;
MARTINUZZI, A .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 1992, 29 (3-4) :217-242
[7]   Incidence of inborn errors of metabolism in British Columbia, 1969-1996 [J].
Applegarth, DA ;
Toone, JR ;
Lowry, RB .
PEDIATRICS, 2000, 105 (01) :art. no.-e10
[8]   Abnormal carnitine distribution in the the muscles of patients with idiopathic inflammatory myopathy [J].
Arenas, J ;
GonzalezCrespo, MR ;
Campos, Y ;
Martin, MA ;
Cabello, A ;
GomezReino, JJ .
ARTHRITIS AND RHEUMATISM, 1996, 39 (11) :1869-1874
[9]   TREATMENT OF MITOCHONDRIAL MYOPATHY DUE TO COMPLEX-III DEFICIENCY WITH VITAMINS K3 AND C - A P-31-NMR FOLLOW-UP-STUDY [J].
ARGOV, Z ;
BANK, WJ ;
MARIS, J ;
ELEFF, S ;
KENNAWAY, NG ;
OLSON, RE ;
CHANCE, B .
ANNALS OF NEUROLOGY, 1986, 19 (06) :598-602
[10]  
ARTS WFM, 1983, LANCET, V2, P581